Zusammenfassung
Die Frühgeborenenretinopathie ist eine der wenigen potenziell zur Erblindung führenden Netzhauterkrankungen des Kindesalters, bei der eine Verhinderung des Sehverlusts durch adäquate und rechtzeitige Therapie möglich ist. Netzhautablative Verfahren wie die Laserkoagulation können die krankheitsursächliche „Vascular endothelial growth factor“ (VEGF)-Sekretion der avaskulären peripheren Netzhaut unterbinden. Eine Blockade der VEGF-Aktivität durch intravitreale Applikation VEGF-hemmender Medikamente hat sich in aktuellen klinischen Studien ebenfalls als wirksam erwiesen. Fortgeschrittene Erkrankungsstadien können den Einsatz chirurgischer Verfahren erforderlich machen. Kenntnisse der Indikationen und Techniken der verschiedenen aktuell zur Verfügung stehenden Therapieverfahren sind entscheidend für die optimale Versorgung der betroffenen Kinder.
Abstract
Retinopathy of prematurity is one of only few potentially blinding retinal diseases of infancy amenable to prevention of visual loss by appropriate and timely therapeutic measures. Retinal ablative therapies, such as laser coagulation eliminate the disease-causing secretion of vascular endothelial growth factor (VEGF) by the avascular peripheral retina. Blockage of VEGF activity by intravitreal administration of VEGF-inhibitory drugs has likewise proven effective in recent clinical studies. Advanced stages of the disease may require surgical intervention. Knowledge of indications and techniques of the different currently available treatment options is crucial to ensure an optimal visual outcome for the affected children.
Literatur
Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216
Autrata R, Krejcirova I, Senkova K et al (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22(5):687–694
Averbukh E (2005) The evidence supporting the early treatment for type 1 retinopathy of prematurity needs further evaluation. Arch Ophthalmol 123:406 (discussion 409–410)
Banach MJ, Ferrone PJ, Trese MT (2000) A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 107:324–327 (discussion 328)
Carneiro AM, Costa R, Falcao MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25–e30
Choi J, Kim JH, Kim SJ et al (2011) Long-term results of lens-sparing vitrectomy for stages 4B and 5 retinopathy of prematurity. Korean J Ophthalmol 25:305–310
Compernolle V, Brusselmans K, Acker T et al (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702–710
Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106:471–479
Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands (2012) Stellungnahme zum Einsatz von Bevacizumab in der Therapie der Frühgeborenenretinopathie. Ophthalmologe 109:197–204
Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694
Engle WA (2004) Age terminology during the perinatal period. Pediatrics 114:1362–1364
European MAE (2007) Lucentis: scientific discussion (March 14, 2007). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/WC500043550.pdf (Zugegriffen: 21.10.2011)
Hairston RJ, Maguire AM, Vitale S et al (1997) Morphometric analysis of pars plana development in humans. Retina 17:135–138
Hardy RJ, Good WV, Dobson V et al (2004) Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 25:311–325
Hartnett ME, Maguluri S, Thompson HW et al (2004) Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina 24:753–757
Hashimoto T, Zhang XM, Chen BY et al (2006) VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development 133:2201–2210
Hinz BJ, Juan E de Jr, Repka MX (1998) Scleral buckling surgery for active stage 4A retinopathy of prematurity. Ophthalmology 105:1827–1830
Hoerster R, Muether P, Dahlke C et al (2012) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol [Epub ahead of print]
Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000–1006
International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999
Jandeck C, Kellner U, Lorenz B et al (2008) Guidelines for ophthalmologic screening of premature infants. Ophthalmologe 105:955–963
Krohne TU, Eter N, Holz FG et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508–512
Krohne TU, Liu Z, Holz FG et al (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682–686
Laws DE, Haslett R, Ashby D et al (1994) Axial length biometry in infants with retinopathy of prematurity. Eye (Lond) 8(Pt 4):427–430
Lorenz B (2011) Kommentar: Anti-VEGF-Einsatz gut abwägen. Klin Monatsbl Augenheilkd 225:488–490
Lorenz B, Spasovska K, Elflein H et al (2009) Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study. Graefes Arch Clin Exp Ophthalmol 247:1251–1262
Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786
Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398
Matsuyama K, Ogata N, Matsuoka M et al (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215–1218
Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615
Moshfeghi DM, Berrocal AM (2011) Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 118:1227–1228
Muether PS, Kribs A, Hahn M et al (2012) No advanced retinopathy of prematurity stages 4 or 5 in a large high-risk German cohort. Br J Ophthalmol 96:400–404
Ng EY, Connolly BP, McNamara JA et al (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 109:928–934 (discussion 935)
Palmer EA, Hardy RJ, Dobson V et al (2005) 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 123:311–318
Patel CK, Walker NJ, Kam JK (2010) A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94:1107–1109
Prenner JL, Capone A Jr, Trese MT (2004) Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 111:2271–2273
Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327–333
Sears JE, Sonnie C (2007) Anatomic success of lens-sparing vitrectomy with and without scleral buckle for stage 4 retinopathy of prematurity. Am J Ophthalmol 143:810–813
Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus (2006) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117:572–576
Seiberth V, Linderkamp O, Vardarli I (1997) Transscleral vs transpupillary diode laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol 115:1270–1275
Wilkinson AR, Haines L, Head K et al (2009) UK retinopathy of prematurity guideline. Eye (Lond) 23:2137–2139
Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA et al (2010) Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 24:931–933
Interessenkonflikt
Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehungen hin: (Kategorie 1: Unterstützung von Forschungsprojekten und klinischen Studien; Kategorie 2: Beratung, Honorare, Reisekosten). Tim U. Krohne (Kat. 1: Novartis; Kat. 2: Novartis); Sabine Aisenbrey (Kat. 1: Bayer Healthcare; Kat. 2: Novartis, Bayer Healthcare); Frank G. Holz (Kat. 1: Novartis, Bayer Healthcare, Alcon, GSK, Pfizer; Kat. 2: Novartis, Bayer Healthcare, Genentech, Alcon, GSK, Pfizer, Acucela, Ophthotec).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krohne, T., Aisenbrey, S. & Holz, F. Aktuelle Therapieoptionen bei Frühgeborenenretinopathie. Ophthalmologe 109, 1189–1197 (2012). https://doi.org/10.1007/s00347-012-2618-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-012-2618-8